Cargando…

Advancing Academic Cancer Clinical Trials Recruitment in Canada

The Canadian Cancer Clinical Trials Network (3CTN) was established in 2014 to address the decline in academic cancer clinical trials (ACCT) activity. Funding was provided to cancer centres to conduct a Portfolio of ACCTs. Larger centres received core funding and were paired with smaller centres to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Rebecca Y., Kato, Diana, Pond, Gregory R., Sundquist, Stephen, Schoales, James, Lalani, Saher, Dancey, Janet E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395528/
https://www.ncbi.nlm.nih.gov/pubmed/34436014
http://dx.doi.org/10.3390/curroncol28040248
_version_ 1783744195204218880
author Xu, Rebecca Y.
Kato, Diana
Pond, Gregory R.
Sundquist, Stephen
Schoales, James
Lalani, Saher
Dancey, Janet E.
author_facet Xu, Rebecca Y.
Kato, Diana
Pond, Gregory R.
Sundquist, Stephen
Schoales, James
Lalani, Saher
Dancey, Janet E.
author_sort Xu, Rebecca Y.
collection PubMed
description The Canadian Cancer Clinical Trials Network (3CTN) was established in 2014 to address the decline in academic cancer clinical trials (ACCT) activity. Funding was provided to cancer centres to conduct a Portfolio of ACCTs. Larger centres received core funding and were paired with smaller centres to enable support and sharing of resources. All centres were eligible for incentive-based funding for recruitment above pre-3CTN baseline. Established performance measures were collected and tracked. The overall recruitment target was 50% above pre-3CTN baseline by Year 4. An analysis was completed to identify predictive success factors and descriptive statistics were used to summarize site characteristics and outcomes. From 2014–2018, a total of 11,275 patients were recruited to 559 Portfolio trials, an overall increase of 59.6% above pre-3CTN baseline was observed in Year 4. Twenty-five (51%) adult centres met the Year 4 recruitment target and the overall recruitment target was met within three years. Three factors that correlated with sites’ achieving recruitment targets were: time period, region and number of baseline trials. 3CTN was successful in meeting its objectives and will continue to support ACCTs and member cancer centres, monitor performance over time and seek continued funding to ensure success, better trial access and outcomes for patients.
format Online
Article
Text
id pubmed-8395528
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83955282021-08-28 Advancing Academic Cancer Clinical Trials Recruitment in Canada Xu, Rebecca Y. Kato, Diana Pond, Gregory R. Sundquist, Stephen Schoales, James Lalani, Saher Dancey, Janet E. Curr Oncol Review The Canadian Cancer Clinical Trials Network (3CTN) was established in 2014 to address the decline in academic cancer clinical trials (ACCT) activity. Funding was provided to cancer centres to conduct a Portfolio of ACCTs. Larger centres received core funding and were paired with smaller centres to enable support and sharing of resources. All centres were eligible for incentive-based funding for recruitment above pre-3CTN baseline. Established performance measures were collected and tracked. The overall recruitment target was 50% above pre-3CTN baseline by Year 4. An analysis was completed to identify predictive success factors and descriptive statistics were used to summarize site characteristics and outcomes. From 2014–2018, a total of 11,275 patients were recruited to 559 Portfolio trials, an overall increase of 59.6% above pre-3CTN baseline was observed in Year 4. Twenty-five (51%) adult centres met the Year 4 recruitment target and the overall recruitment target was met within three years. Three factors that correlated with sites’ achieving recruitment targets were: time period, region and number of baseline trials. 3CTN was successful in meeting its objectives and will continue to support ACCTs and member cancer centres, monitor performance over time and seek continued funding to ensure success, better trial access and outcomes for patients. MDPI 2021-07-28 /pmc/articles/PMC8395528/ /pubmed/34436014 http://dx.doi.org/10.3390/curroncol28040248 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Xu, Rebecca Y.
Kato, Diana
Pond, Gregory R.
Sundquist, Stephen
Schoales, James
Lalani, Saher
Dancey, Janet E.
Advancing Academic Cancer Clinical Trials Recruitment in Canada
title Advancing Academic Cancer Clinical Trials Recruitment in Canada
title_full Advancing Academic Cancer Clinical Trials Recruitment in Canada
title_fullStr Advancing Academic Cancer Clinical Trials Recruitment in Canada
title_full_unstemmed Advancing Academic Cancer Clinical Trials Recruitment in Canada
title_short Advancing Academic Cancer Clinical Trials Recruitment in Canada
title_sort advancing academic cancer clinical trials recruitment in canada
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395528/
https://www.ncbi.nlm.nih.gov/pubmed/34436014
http://dx.doi.org/10.3390/curroncol28040248
work_keys_str_mv AT xurebeccay advancingacademiccancerclinicaltrialsrecruitmentincanada
AT katodiana advancingacademiccancerclinicaltrialsrecruitmentincanada
AT pondgregoryr advancingacademiccancerclinicaltrialsrecruitmentincanada
AT sundquiststephen advancingacademiccancerclinicaltrialsrecruitmentincanada
AT schoalesjames advancingacademiccancerclinicaltrialsrecruitmentincanada
AT lalanisaher advancingacademiccancerclinicaltrialsrecruitmentincanada
AT danceyjanete advancingacademiccancerclinicaltrialsrecruitmentincanada